CVS Health Split Leaves PBM Vertical Integration and Patient Cost Pressures Largely Intact

CVS Health disclosed plans to divide its operations into a retail-pharmacy-insurance entity and a separate PBM-focused business without divesting Caremark. This structure retains shared ownership incentives that allow spread pricing and formulary steering to persist. Revenue data show PBM margins have grown from 2 percent to over 5 percent of drug spend in the past decade while patient out-of-pocket costs for specialty drugs rose 18 percent annually according to CMS figures.

Analyses from the FTC’s 2024 interim report and a Health Affairs study of 12 million claims both document that integrated PBMs generate higher net prices than non-integrated competitors even after rebates. The CVS move mirrors earlier restructurings by UnitedHealth and Cigna that preserved similar ownership ties and produced no measurable reduction in list prices within 18 months.

The split is therefore unlikely to alter the underlying reimbursement mechanics that reward higher list prices. Regulators have signaled continued scrutiny through ongoing investigations into spread pricing and steering, yet legislative proposals for mandatory separation remain stalled.

Next steps include state-level transparency laws taking effect in 2025 and potential FTC enforcement actions that could force asset divestitures if the new entities continue coordinated pricing strategies.